FDA approves over-the-counter Primatene Mist inhaler

This article was originally published here

Amphastar PharmaceuticalsThe FDA this week approved Amphastar Pharmaceuticals‘ (NSDQ:AMPH) over-the-counter Primatene Mist inhaler for the temporary relief of mild symptoms of intermittent asthma.

The original version of Amphastar’s Primatene Mist device was taken off the market in 2011 because it contained chlorofluorocarbon propellants – a chemical compound that is linked to depletion of the Earth’s ozone layer. The company’s latest product contains hydrofluoroalkane propellants, which are permitted under current U.S. law.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves over-the-counter Primatene Mist inhaler appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply